Cardiovascular Diseases D002318

Diseases [C] » Cardiovascular Diseases

Description

Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.   MeSH

Subtype Terms (5)

Cardiovascular Abnormalities
22 drugs (15 approved, 7 experimental)

Cardiovascular Infections
 

Heart Diseases
369 drugs (243 approved, 126 experimental)

Pregnancy Complications, Cardiovascular
 

Vascular Diseases
172 drugs (119 approved, 53 experimental)


Phase 4 Indicated Drugs (145)

Phase 3 Indicated Drugs (103)

Other Experimental Indicated Drugs (137)


Organization Involved with Phase 4 Indications (222)

Fukuoka University

Fundação de Amparo à Pesquisa do Estado de São Paulo

Garvan Institute of Medical Research

George Washington University

Gilead Sciences

GlaxoSmithKline

Government of Taiwan

Hamilton Health Sciences Corporation

Harbin Medical University

Harvard University

Heart and Stroke Foundation of Canada

Helena Laboratories Point of Care

Herlev Hospital

HLS Therapeutics, Inc

Hospital Alessandro Manzoni Lecco

Hospital Italiano de Buenos Aires

Hospital Regional 10 de Octubre, ISSSTE

Hospital Universitario Arnau de Vilanova de Lleida

Icahn School of Medicine at Mount Sinai

Imam Abdulrahman Bin Faisal University

Indiana University

Inova Health System

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Isfahan University

Italian Diabetes Society

Italian Society of Diabetology

Italian Society of Invasive Cardiology

Janssen Pharmaceutica NV

Japan Foundation for Aging and Health

Japan Heart Foundation

Johannes Gutenburg University

Johns Hopkins University

Kaiser Permanente

Keio University

King Fahad Armed Forces Hospital

Kitasato University

Konkuk University

Korea University

Kowa

Kumamoto University

KVT-Study Group

Kyowa Hakko Kogyo

Lantheus Medical Imaging

Leiden University

Lepu Medical Technology (Beijing) Co., Ltd.

Les Laboratoires des Médicaments Stériles

LifeBridge Health

Maastricht University

Mars, Inc.

McGill University

Mclean Hospital

McMaster University

Michael J. Gill Mental Health Clinic

MicroPort Orthopedics Inc.

Minneapolis Heart Institute

Monash University

Nang Kuang Pharmaceutical Co., Ltd.

National Cheng Kung University

National Heart Foundation, Australia

National Heart, Lung, and Blood Institute (NHLBI)

National Institute for Health Research, United Kingdom

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Aging (NIA)

National Institutes of Health (NIH)

National Taiwan University

Netherlands Heart Foundation

Newcastle University

New York University

Northwestern University

Novo Nordisk

Ohio State University

Ontario HIV Treatment Network

Orexigen Therapeutics, Inc

Orion Corporation

Osaka University

OSCAR Study

Otsuka

People's Liberation Army of China

Pfizer

Radboud University

Research Maatschap Cardiologen Rotterdam Zuid

Richmond University

Royal College of Surgeons, Ireland

RUMCN

Rundo International Pharmaceutical Research & Development Co.,Ltd.

Rush University

Saga University

Samjin Pharmaceutical Co., Ltd.

Schweizerischer Nationalfonds

Seoul National University

Sheffield Hallam University

Showa University

Stanford University

State University of Londrina

Steno Diabetes Center

St. Marianna University School of Medicine

Sun Yat-Sen University

Synmosa Biopharma Corp.

Takeda

Tel Aviv University

The Japanese Society of Hypertension

The Massachusetts Mental Health Center

The National Centre in HIV Epidemiology and Clinical Research, Sydney

The Physicians' Services Incorporated Foundation

The University of Texas, Dallas

Thrombolysis In Myocardial Infarction Academic Research Organization

Tokai University

Tsinghua University

Tufts University

Unity Health Toronto

Organization Involved with Phase 3 Indications (212)

Organization Involved with Phase 2 Indications (73)

Organization Involved with Other Experimental Indications (151)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.